Last $5.25 USD
Change Today -0.13 / -2.42%
Volume 367.1K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Key Developments

XenoPort, Inc. and the National Institute on Alcohol Abuse & Alcoholism Announce Clinical Trial Agreement to Study Horizant as Potential Treatment for Alcohol Use Disorder

XenoPort, Inc. and the National Institute on Alcohol Abuse and Alcoholism announced that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application (sNDA) submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

XenoPort, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM

XenoPort, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.

Xenoport, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Xenoport, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $5,334,000 compared to $2,086,000 a year ago. Loss from operations was $19,333,000 compared to $24,187,000 a year ago. Net loss was $19,387,000 compared to $24,381,000 a year ago. Basic and diluted net loss per share was $0.31 compared to $0.51 a year ago. For the six months, the company's total revenues were $8,709,000 compared to $2,545,000 a year ago. Loss from operations was $39,816,000 compared to $47,816,000 a year ago. Net loss was $39,935,000 compared to $47,929,000 a year ago. Basic and diluted net loss per share was $0.67 compared to $1.01 a year ago. The increase in revenues in both the second quarter and six months ended June 30, 2014 was principally due to HORIZANT net product sales, which totaled $4.9 million and $7.9 million for the second quarter and six months ended June 30, 2014, respectively.

Xenoport, Inc. to Report Q2, 2014 Results on Aug 06, 2014

Xenoport, Inc. announced that they will report Q2, 2014 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2014

Xenoport, Inc., Q2 2014 Earnings Call, Aug 06, 2014

Xenoport, Inc., Q2 2014 Earnings Call, Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $5.25 USD -0.13

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Access Pharmaceuticals Inc $0.27 USD -0.0048
Biocon Ltd 498.95 INR +0.75
BioDelivery Sciences International Inc $16.26 USD -0.83
Depomed Inc $15.16 USD -0.03
Flamel Technologies SA $14.24 USD -0.07
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.6x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.